Summary Inhibitors of ornithine decarboxylase (ODC), such as a-difluoromethylornithine (DFMO), may influence the cytotoxicity of anti-tumour agents that interact with DNA. Intracellular levels of putrescine and spermidine were markedly reduced by ODC inhibitors while the level of spermine, which is the main polyamine in nuclei, was unchanged. By combining a novel inhibitor of ODC, such as (2R, 5R)-6-heptyne-2,5-diamine (MDL 72.175, MAP), with an inhibitor of S-adenosylmethionine decarboxylase (SAMDC), such as 5'-{[(Z)-4-aminobut-2-enyl]methylamino}-5'-deoxyadenosine (MDL 73.81 1, AbeAdo), spermine was selectively depleted in a human ovarian cancer cell line OVCAR-3 (i.e. spermine became almost undetectable whereas the levels of spermidine and putrescine were not affected). The . The addition of spermine before drug treatment restored the sensitivity to the DNA topoisomerase 11 inhibitors, thus indicating that the reduced effect was related to the intracellular spermine level. The reason for the reduction in cytotoxicity is unclear, but it does not appear to be related to a cell cycle effect or to a decrease in the intracellular level of DNA topoisomerase 11. Drugs that modify polyamine biosynthesis are under early clinical development as potential new anti-tumour agents. These findings illustrate the need for caution in combining such drugs with DNA topoisomerase 11 inhibitors.
Summary Inhibitors of ornithine decarboxylase (ODC), such as a-difluoromethylornithine (DFMO), may influence the cytotoxicity of anti-tumour agents that interact with DNA. Intracellular levels of putrescine and spermidine were markedly reduced by ODC inhibitors while the level of spermine, which is the main polyamine in nuclei, was unchanged. By combining a novel inhibitor of ODC, such as (2R, 5R)-6-heptyne-2,5-diamine (MDL 72.175, MAP) , with an inhibitor of S-adenosylmethionine decarboxylase (SAMDC), such as 5'-{[(Z)-4-aminobut-2-enyl]methylamino}-5'-deoxyadenosine (MDL 73.81 1, AbeAdo), spermine was selectively depleted in a human ovarian cancer cell line OVCAR-3 (i.e. spermine became almost undetectable whereas the levels of spermidine and putrescine were not affected). The depletion of spermine blocked DNA synthesis with a consequent accumulation of cells in the G, phase of the cell cycle. Pretreatment with MAP plus AbeAdo did not change the cytotoxicity of alkylating agents, such as L-phenylalanine mustard (L-PAM), 1,4-bis (2'-chloroethyl)-1, 4-diazabicyclo-[2.2.1] heptane diperchlorate (DABIS), 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), cis-diamminedichloroplatinum (II) (cis-DDP), N-deformyl-N-[4-N-N,N-bis (2-chloroethylamino) benzoyl] (tallimustine) or CC-1065, whereas it markedly reduced the cytotoxicity of DNA topoisomerase 11 inhibitors, such as doxorubicin (DX) and 4'-demethylepipodophyllotoxin-5-(4,6-O)-ethylidene-P-D-glycopyranoside . The addition of spermine before drug treatment restored the sensitivity to the DNA topoisomerase 11 inhibitors, thus indicating that the reduced effect was related to the intracellular spermine level. The reason for the reduction in cytotoxicity is unclear, but it does not appear to be related to a cell cycle effect or to a decrease in the intracellular level of DNA topoisomerase 11. Drugs that modify polyamine biosynthesis are under early clinical development as potential new anti-tumour agents. These findings illustrate the need for caution in combining such drugs with DNA topoisomerase 11 inhibitors.
Keywords: polyamines; novel inhibitor of ornithine decarboxylase; MAP; inhibitor of SAMDC; AbeAdo; anti-cancer agents One of the more interesting characteristics of polyamines is their apparent interaction with DNA (Feuerstein et al, 1991) . These polycations seem to exert specific effects besides their nonspecific electrostatic interactions. Studies in vitro have demonstrated that polyamines, mostly spermidine and spermine, are involved in the conversion of B-DNA into A and Z forms of DNA, and help in DNA condensation (Thomas and Messner, 1988; Feuerstein et al, 1991; Haworth et al, 1991) . According to molecular mechanistics calculations spermine binds to the major groove producing a bend in B-DNA (Feuerstein et al, 1990) .
Using 'real' DNA sequences from Saccharomyces cerevisiae, rather than the homopolymeric or alternating co-polymer sequences, it has been found that the secondary structure might be the principal factor in polyamine binding to DNA. Polyamines seem to bind strongly to particular DNA sequences, e.g. the TATA element, and thus may play an important and dynamic role in chromatin structure and function in vivo (Xiao et al, 1991) .
Indirect evidence has been reported of nuclear functions of polyamines in mammalian cells (Hougaard, 1992) . Spermine is present in the highest concentration in the mammalian cell nucleus (Mach et al, 1982) , although definitive data on cellular localization and compartmentalization of polyamines have not been reported.
Polyamine metabolism is highly regulated, indicating that polyamines have cellular functions beyond those of simple cations (Pegg, 1988) . Treatment with inhibitors of polyamine metabolism alters the sensitivity of cultured cells to DNA-reactive chemotherapeutic drugs, such as cis-diamminedichloroplatinum (II) (cis-DDP) (Oredsson et al, 1982) , nitrosoureas (Seidenfeld and Sprague, 1990) and doxorubicin (DX) (Seidenfeld et al, 1986a) . These investigations have been made with a-difluoromethylornithine (DFMO), a specific and irreversible inhibitor of ornithine decarboxylase (EC 4.1.1.17, ODC) (Metcalf et al, 1978) . ODC is the first and rate-limiting enzyme in the polyamine biosynthetic pathway that catalyses de novo synthesis of putrescine (Pegg, 1988) .
S-adenosylmethionine decarboxylase (EC 4.1.1.50, SAMDC) is the rate-limiting enzyme in the synthesis of spermidine and spermine from putrescine (Pegg, 1988) . The combination of specific inhibitors of ODC and SAMDC can block polyamine biosynthesis, causing a remarkable drop in spermine levels (Desiderio et al, 1993) . This result cannot be obtained with any ODC inhibitor used alone (Pegg, 1988) .
In the present study, we examined the effects of alkylating agents and DNA topoisomerase II inhibitors on the survival of the human ovarian carcinoma OVCAR-3 cell line after 72-h pretreatment with the combination of (2R,5R)-6-heptyne-2,5-diamine (MDL 72.175, MAP) and 5'-{[(Z)-4-aminobut-2-enyl]methylamino)-5'-deoxyadenosine (MDL 73.811, AbeAdo) inhibitors, respectively of ODC (Mamont et al, 1984) and SAMDC (Danzin et al., 1990; Stjemborg et al., 1993) . OVCAR-3 ovarian carcinoma cells were almost completely depleted of spermine and accumulated in the G,-phase 72 h after the combined inhibitory treatment. The depletion of spermine did not affect the cytotoxicity of alkylating agents, but it markedly reduced the cytotoxicity of DNA-topoisomerase II inhibitors.
MATERIALS AND METHODS
Reagents and culture ware DX and N-deformyl-N-[4-N-N,N-bis (2-chloroethylamino) benzoyl] (tallimustine) were kindly provided by UpjohnPharmacia, Milan, Italy; 1 ,3-bis (2-chloroethyl)-l-nitrosourea (BCNU), 1 ,4-bis (2'-chloroethyl)- 
Cells and culture conditions
The OVCAR-3 human ovarian carcinoma cell line was used. For all these experiments, cells were conditioned to grow in RPMI-1640 medium supplemented with 10% horse serum that does not contain amino-oxidases which can oxidize spermine to toxic products (Kaminska et al, 1990) . The doubling time and morphology of the cells growing in horse serum were the same as cell cultures growing in fetal bovine serum.
Polyamine inhibitor treatment
Cells were seeded at a concentration of 20 000 cells ml-' and, after at least two doubling times, 100 gM MAP and 25 jiM AbeAdo were added to the culture medium for 72 h. The concentrations of MaP and AbeAdo were selected on the basis of previous work (Desiderio et al, 1993) .
Anti-cancer drug treatment and clonogenicity
The effect of drug treatment was evaluated on exponentially growing cells and on cells pretreated for 72 h with the combination of the two inhibitors of polyamine biosynthetic enzymes. The exponentially growing cells were seeded at a lower density than those cells that were treated with MAP/AbeAdo so as to reach the same cellular density at the time of the anti-cancer agents' treatment. The control and inhibitor-pretreated cells were treated for 1 h with different concentrations of the anti-cancer agents. In another set of experiments, reversion of the effect of MAP plus AbeAdo was examined by adding 1 mm spermine 1 h before drug treatment.
At Flow cytometric analysis of cell-cycle phase distribution and BUdR uptake
Monoparametric conventional cell-cycle analysis using propidium iodide (a specific fluorescent dye for DNA) was carried out in control and MAP/AbeAdo-treated cells at different times of treatment and after inhibitor washout using a FACStar plus (Becton Dickinson, CA, USA) instrument coupled to a Hewlett Packard computer system. Cell cycle phase percentages were calculated on at least 20 000 cells by the method of Krishan and Frei (1976) . For biparametric BUdR/DNA, 30 jM BUdR was added to the cells for 20 min during the inhibitor treatment and, after the inhibitor washout, cells were fixed with 70% ethanol at 40C. The cells were washed with phosphate-buffered saline (PBS), and DNA was denatured with 3N HCl for 30 min at room temperature. Denaturation was stopped by the addition of 0. IM sodium borate (pH 8.5) in excess, and the cells were centrifuged. The cells were incubated for 15 min with a solution containing 0.5% Tween 20 in PBS and 1% normal goat serum. BUdR uptake was detected after 1-h incubation with 100 jl of anti-BUdR monoclonal antibody (diluted 1:10 in 0.5% Tween 20 in PBS), followed by another 1-h incubation with 100 jil of FITC-conjugated goat anti-mouse IgG (diluted 1:50 in 0.5% Tween 20 in PBS). After washing with PBS, the cells were resuspended in a solution of 5 jig ml-' propidium iodide in PBS and 10 000 U of ribonuclease for at least 2 h in the dark (Erba et al, 1995) .
Determination of polyamines
Cells from three flasks were pooled (1.5 x 106 cells) at various times after MAP/AbeAdo treatment or inhibitor washout. Cellular extracts were prepared in 200 jil of 0.2 N perchloric acid by ultrasonication and were centrifuged at 5000 r.p.m. for 20 min with an Eppendorf microcentrifuge. Analysis was carried out using high pressure liquid chromatography (Desiderio, 1992) , with modifications (Loser et al, 1988) . A C,8 reverse-phase Nova-Pak column (4-jm particle size, 150 x 3.9 mm, Waters) was used for chromatographic separation of the polyamines, which were derivatized post-column with o-phthalaldehyde. The protein content was determined using the Lowry method (Lowry et al, 1951 The main purpose of the study was to investigate whether the potential cytotoxic activity of several anti-cancer agents, with different structures and modes of action, was affected by the depletion of spermine observed after MAP/AbeAdo treatment. Figure 4 shows the clonogenicity of cells treated with conventional alkylating agents such as L-PAM, DABIS, BCNU, cis-DDP or with some new alkylating compounds, such as tallimustine and CC-1065, under the inhibitory treatment. No statistically significant differences in cytotoxicity were observed in sperminedepleted or non-depleted cells. However, when spermine-depleted cells were treated with DX or VP-16, two topoisomerase II inhibitors, cytotoxicity was markedly lower. The addition of 1 mM spermine before drug treatment restored the sensitivity to the DNA topoisomerase II inhibitors, thus indicating that the reduction was in effect, related to the spermine level ( Figure 5 ). In fact, the addition of 1 mm spermine raised the intracellular spermine level as observed after 20 ItM spermine without modifying the cell cycle distribution (data not shown).
Treatment with MAP/AbeAdo did not reduce DNA topoisomerase IIa content as assessed by Western blot analysis (Figure 6 ).
DISCUSSION
The present study shows that the combination of an ODC inhibitor, such as MAP, and a SAMDC inhibitor, such as AbeAdo, selectively depletes intracellular spermine in human ovarian cancer cells. As expected, the depletion of spermine blocked cell growth without any detectable cytotoxicity. The fact that cells with minimum levels of spermine but with normal levels of the other polyamines accumulated in the G, phase of the cell cycle was consistent with the view that spermine might be involved in DNA British Journal of Cancer (1997) 75(7) synthesis (Marton and Pegg, 1995) . On adding spermine, the G1 block was rapidly reversed, and the cells progressed normally through the other phases of the cell cycle. Therefore, the combination of MAP/AbeAdo provides a suitable system for investigating the biological and pharmacological influence of spermine which is the principal polyamine in the nucleus (Hougaard, 1992) . In vitro studies indicate that spermine is involved in the modification of the structure and function of chromatin (Feuerstein et al, 1991; Haworth et al, 1991 ). Therefore, the spermine level may influence the activity of anti-tumour agents by modifying their interaction with chromatin. In order to investigate this point, we selected eight compounds with different structures, six of them alkylating agents and two DNA-topoisomerase II inhibitors. The alkylating agents cause different DNA lesions. L-PAM and DABIS formi DNA interstrand cross-links between guanine N7. In addition, these two drugs form DNA monoadducts at guanine N7 position which differ slightly in their sequence specificity (Broggini et al, 1990) . Cis-DDP forms DNA interstrand and intrastrand cross-links, the latter being quantitatively prevalent (Sherman et al, 1985; Eastman, 1986) . BCNU forms DNA interstrand cross-links between guanines and cytosines located in a GC base pair, which are chemically different from those formed by nitrogen mustards or cis-DDP (Cavanaugh et al, 1984; Seidenfeld et al, 1987) . Mechanistically more different are tallimustine and CC-1065 which do not alkylate guanines but only N3 adenines with high sequence specificity (Broggini et al, 1991) . The depletion of spermine did not influence the cytotoxicity of any of the alkylating drugs. This is in apparent conflict with some published findings. Pretreatment with inhibitors of ODC, such as DFMO or MAP, was in fact reported to change BCNU and cis-DDP cytotoxicity (Chang et al, 1987; Milam et al, 1989; Hunter et al, 1990) . It is worth noting that separate treatment with these inhibitors lowered spermidine and putrescine levels, while spermine remained unchanged. Therefore the results of the present study, in which, by combining MAP and AbeAdo, almost complete depletion of spermine was obtained, cannot be compared with the previous studies in which the other two polyamines were decreased. A different modulation of the three polyamines appears to influence the effects of the drugs in a different way. This is difficult to explain, but it may be the consequence of the different functions of the three polyamines in the cells, which have been only partly elucidated (Hougaard, 1992; Marton and Pegg, 1995) .
To our knowledge, no reports have been published on the influence of polyamine levels on alkylating agents that bind in the DNA minor groove, such as tallimustine and CC-1065 (Hurley et al, 1988; Arcamone et al, 1989) . These two drugs bind in the minor groove of AT-rich sequences and alkylate N3 adenine with a high degree of sequence specificity (Broggini et al, 1995) . Depletion of spermine did not cause any detectable change in the cytotoxicity of both minor groove binders. These results could be expected on the basis of the more recent theoretical studies on the spermine-DNA interaction. In fact, whereas previous studies (Liquori et al, 1967 ) suggested a more favourable interaction of spermine within the minor groove of DNA, more recently Feuerstein et al (1990) proposed a model which supports the interaction with the major groove, based on both structural and energetic grounds.
In contrast to what has been found for alkylators, it appears that spermine depletion caused a reduction in the cytotoxicity of DNA topoisomerase II inhibitors. This was found both for DX, which intercalates into DNA (Arcamone et al, 1989) , and for VP-16, which does not bind significantly to DNA. The reason for the loss of effect of the DNA topoisomerase II inhibitor is unclear. The following explanations can be suggested: (a) the arrest of cells in the G, phase following spermine depletion might reduce the cytotoxic effect of drugs known to be cell cycle specific (Seidenfeld et al, 1986b; Pohjanpelto et al, 1994) ; (b) spermine depletion might be associated with a decrease in cellular levels of DNA topoisomerase II, known to be important in the activity of these compounds; (c) DNA binding and the activity of DNA topoisomerase II could be affected by the local changes in the structure and charge of chromatin, probably consequent to the drop in spermine level (Pommier et al, 1989) . The first two possibilities appear unlikely as sensitivity to DNA topoisomerase II inhibitors was completely restored by adding spermine before drug exposure, even though the cell-cycle distribution was not modified by the polyamine. DNA topoisomerase II levels were unchanged after treatment with MAP/AbeAdo. The third explanation seems the most likely, considering that changes in polyamine levels may modify the activity of other DNA-processing enzymes (Basu et al, 1992) and are believed to affect the DNA binding of transcription factors (Celano et al, 1989) .
The reduced activity of DNA topoisomerase II inhibitors after depletion of intracellular spermine suggests the need for caution when combining novel drugs that modify polyamine biosynthesis, such as CGP 48664 (Regenas et al, 1994) , which is currently under clinical investigation, with topoisomerase II inhibitors.
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